Hospital Clinic de Barcelona
Hospital Clinic de Barcelona
Barcelona, Spain31 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia | Female Pattern Baldness, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alopecia, androgenetic alopecia, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Active, not recruiting | Phase 3 | 2026-09-16 | NCT05888922 | |
| Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Not stated | 2026-09-16 | NCT02071134 | |
| A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Shock, Cardiogenic, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT06832722 | |
| Vercise™ DBS Dystonia Prospective Study | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, dystonic disorder, nervous system disorder | Recruiting | Not stated | 2026-09-11 | NCT02686125 | |
| A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria | Active, not recruiting | Not stated | 2026-09-03 | NCT05776472 | |
| A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study | Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin Abnormalities, Skin and Connective Tissue Diseases, connective tissue disorder, epidermolysis bullosa, epidermolysis bullosa dystrophica, hereditary disease, hereditary skin disorder, junctional epidermolysis bullosa, skin disorder, vesiculobullous skin disease | Recruiting | Phase 2 | 2026-08-12 | NCT06594393 | |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06731478 | |
| ATLAS (AltaValve) Pivotal Trial | cardiovascular disorder, heart disorder, heart valve disorder, mitral valve insufficiency | Recruiting | Not applicable | 2026-08-03 | NCT06465745 | |
| Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 1 | 2026-07-30 | NCT05464030 | |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Active, not recruiting | Phase 3 | 2026-07-17 | NCT04603495 | |
| Post-Market Clinical Follow Up Study With Navitor Valve | Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart valve disorder | Recruiting | Not stated | 2026-07-10 | NCT06008080 | |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 3 | 2026-07-02 | NCT06819007 | |
| Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Active, not recruiting | Phase 2 | 2026-05-27 | NCT06602193 | |
| The CATALINA Study | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Not stated | 2026-05-22 | NCT05008081 | |
| Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-05-14 | NCT05296746 | |
| Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Recruiting | Phase 1 / Phase 2 | 2026-05-11 | NCT06501625 | |
| Comparison of EVAR and ESAR for Infrarenal Aortic Aneurysms With a Wide Proximal Neck | Aneurysm, abdominal aortic aneurysm, aortic aneurysm, aortic disorder, cardiovascular disorder, vascular disorder | Recruiting | Not applicable | 2026-05-11 | NCT05484115 | |
| Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-04-24 | NCT05982093 | |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | cardiovascular disorder, heart disorder, heart failure, heart valve disorder, mitral valve insufficiency | Recruiting | Not applicable | 2026-04-13 | NCT03142152 | |
| A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC | Bacterial Infections and Mycoses, Chronic Disease, Chronic Spontaneous Urticaria, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Hypersensitivity, Immediate, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin Diseases, Eczematous, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Suppuration, alopecia, alopecia areata, atopic eczema, bacterial infectious disease, chronic urticaria, dermatitis, disorder of pilosebaceous unit, hereditary disease, hereditary skin disorder, hidradenitis, hidradenitis suppurativa, hypopigmentation of the skin, hypotrichosis, immune system disorder, psoriasis, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, skin pigmentation disorder, skin vascular disease, sweat gland disorder, urticaria, vitiligo | Active, not recruiting | Not stated | 2026-03-20 | NCT03661866 | |
| A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-03-17 | NCT05257083 | |
| SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-02-27 | NCT03589222 | |
| Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-02-13 | NCT04041310 | |
| Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, acquired thrombotic thrombocytopenic purpura, blood coagulation disease, blood platelet disease, hematologic disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombophilia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura | Active, not recruiting | Not stated | 2026-02-11 | NCT05046717 | |
| Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms. | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 | 2026-01-20 | NCT06359002 |